Read More

Ascendis Pharma And Royalty Pharma Enter Into $150M Royalty Funding Agreement; Proceeds To Support Continued Development And Commercialization Of Endocrine Rare Disease Products, And General Corporate Purposes

- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes   COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis

ASND